Rituximab occupies an unusual position in our catalogue — it's one of the few products we export with two genuinely distinct buyer profiles, oncology hospitals treating blood cancers and rheumatology clinics treating autoimmune disease, and we handle documentation and dosing-guidance conversations differently depending on which one is placing the order. It works by targeting CD20, a protein found on the surface of B-cells, effectively depleting the population of B-cells responsible for either malignant proliferation (in lymphoma/leukemia) or autoimmune antibody production (in rheumatoid arthritis and related conditions).

• Oncology indications: Non-Hodgkin's lymphoma (multiple subtypes), chronic lymphocytic leukemia
• Autoimmune indications: Rheumatoid arthritis (in combination with methotrexate, for patients who've failed TNF-inhibitor therapy), pemphigus vulgaris, ANCA-associated vasculitis
• Mechanism: Binds CD20 on B-lymphocytes, triggering B-cell depletion through multiple immune-mediated pathways
• Dosing pattern varies significantly by indication: Oncology protocols typically involve weekly or cycle-based dosing over several months; rheumatoid arthritis protocols use a twice-yearly maintenance schedule — a distinction that affects order volume and frequency for distributors serving each buyer type

Rituximab's B-cell-depleting mechanism, while therapeutically valuable, leaves patients meaningfully more vulnerable to infection during and after treatment — which shapes both the pre-treatment screening protocol and the post-infusion monitoring window.

• Contraindications: Severe active infection, significant pre-existing immunosuppression
• Infusion-reaction protocol: Pre-medication (antihistamine, antipyretic, corticosteroid) required before every infusion given documented reaction risk, particularly with the first dose
• Hepatitis B screening: Strongly recommended before first infusion — Rituximab carries a documented risk of reactivating dormant Hepatitis B infection, which can be severe
• Contraception requirement: Required for a minimum of 12 months following the final dose
• Pregnancy/breastfeeding: Not recommended — B-cell depletion can affect the developing immune system

Stock status: In stock for export

• Logistics: GDP-compliant cold-chain export (2–8°C)
• Coverage: Global, serving both oncology hospital networks and rheumatology-focused pharmaceutical distributors
• Tracking: Full shipment tracking included as standard

What is Rituximab used for?

Treats blood cancers like Non-Hodgkin's lymphoma and CLL, as well as autoimmune conditions like rheumatoid arthritis.

Get Rituximab price from a GMP-compliant Indian supplier — how?

Send strength, destination, and intended use (oncology or autoimmune) for a verified quote.

Does it suppress immunity?

Yes — it depletes B-cells, increasing infection risk, so active infections must be resolved before starting treatment.

Is it safe in pregnancy?

No, it's not recommended during pregnancy or breastfeeding due to its effect on B-cell immunity.

Who supplies Rituximab from India?

WHO-GMP certified manufacturer with full export documentation for both oncology and rheumatology buyers.